Tiziana life sciences reports positive 3-month neuroimaging scores in multiple sclerosis patients receiving intranasal foralumab

New york, april 25, 2024 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in white matter z-scores measured from pet images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-spms). white matter z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
TLSA Ratings Summary
TLSA Quant Ranking